MS Patients Face Setbacks After NHS Switch to Cheaper Drug
26 Feb 2025
The NHS's decision to switch multiple sclerosis (MS) patients from Tysabri, a well-established treatment, to Tyruko, a cheaper biosimilar drug, has led to significant complications for many individuals. These complications, including relapses of their MS symptoms, debilitating side effects, and hospitalizations, have raised concerns about the long-term consequences of this...
Read More
